



RELIANCE INDUSTRIES LIMITED  
Attn: Dr. Y.B. Vasudeo, Sr. Vice President  
Product Application & Research Centre (PARC)  
Swastik Mill Compound  
V.N. Purav Marg, Chembur  
Mumbai - 400 071, INDIA

NOV 25 2005

Dear Sir/Madam:

The Food and Drug Administration acknowledges receipt of the following Drug Master File (DMF) submission:

**DMF Number Assigned:** 18919 **Date of Submission:** October 14, 2005

**DMF Type:** III

**Title of Submission:** Polyvinyl Chloride (PVC) Raw Material Grade Reon 60-11 **as manufactured in Gujarat, India**

**Holder of Submission:** Reliance Industries Limited

**Submitted by:** Reliance Industries Limited

**Agent(s):** None

All subsequent correspondence to this DMF should be identified with the information as provided above. Submissions to the DMF should be forwarded in duplicate.

Your DMF will be reviewed only in connection with the New Drug Applications, Abbreviated New Drug Applications, Investigational New Drug Applications or any DMFs it is intended to support.

The holder of the DMF is responsible for compliance with the Regulation Title 21 Code of Federal Regulations Part 314.420 as interpreted in "The Guideline for Drug Master Files" [HEW (FDA) 79-3072]. This information can be found at [www.fda.gov/cder/guidance/index.htm](http://www.fda.gov/cder/guidance/index.htm). This includes adhering to the statement of the commitment and providing the FDA with the following:

- an annual list of all individuals and firms authorized to make reference to the DMF and identification of any party whose authorization has been withdrawn;
- an annual update of the DMF or a statement that the DMF remains current (whichever is appropriate); and
- amendments which incorporate any changes in the DMF. Parties authorized to reference the DMF should be notified of the changes before implementation.

Sincerely,

For

Sharon L. Brownell  
Public Health Analyst  
Manager of Drug Master Files  
Office of Information Management  
Records Repository Team